Acorda Therapeutics: PharmaVitae Report

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Features and benefits

• Gain insight into Acorda Therapeutics' strategic outlook
• Analyze company sales forecasts by product

Highlights

Acorda obtained rights to its lead product, Ampyra, in 2003. In January 2010, the FDA approved the drug to improve walking in patients with MS. Acorda recorded $211m in Ampyra sales in 2011 and it is also being developed to improve walking in patients with cerebral palsy and those with chronic debilitation from a stroke.

Your key questions answered

• Benchmark Acorda Therapeutics' performance against key rivals in the prescription pharmaceutical sector
• See how, following Zanaflex's patent expiry, Acorda will become increasingly dependent on Ampyra's sales

Table Of Contents

ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
Ampyra (dalfampridine)
Ampyra clinical trials in multiple sclerosis
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Ampyra shows significant effects, but only in a third of patients
Seizure risk necessitates REMS program
Ampyra is a useful drug for multiple sclerosis, but payers are likely to restrict uptake due to its high price
Marketing of Ampyra has been successful to date
Zanaflex (tizanidine hydrochloride)
Diazepam nasal spray (DZNS)
Early-stage products
GGF-2
Chondroitinase

FINANCIAL ANALYSIS
Financial performance overview
Operating costs and profit analysis, 2005–11
Operating costs and profit analysis, 2011–17

APPENDIX
References
Exchange rates

List Of Tables

Table: Acorda R&D pipeline
Table: Acorda key catalysts
Table: Acorda product portfolio overview ($m), 2011–17
Table: Overview of pivotal trial data for Ampyra, 2011
Table: Ampyra ongoing trials
Table: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
Table: Acorda operating revenue/cost analysis ($m), 2005–11
Table: Acorda operating revenue/cost analysis ($m), 2011–17
Table: Exchange rates, 2011

List Of Figures

Figure: PharmaVitae Explorer
Figure: Acorda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
Figure: Acorda product sales ($m), 2011–17
Figure: Ampyra SWOT analysis in multiple sclerosis, 2011
Figure: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
Figure: Acorda operating/cost performance ($m), 2004–16